Tresiba® showed an overall lower risk of hypoglycaemia and significantly lower HbA1c when compared to insulin glargine U300 in people with type 2 diabetes
(WorldNews Denmark)

This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. Tresiba® showed an overall lower risk of hypoglycaemia and significantly lower HbA1c when compared to insulin glargine U300 in people with type 2 diabetes Barcelona, Spain, 19 September 2019 - According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes uncontrolled on basal insulin with or without oral anti-diabetic drugs (OADs). Results from the...